A
KYMR icon

AlphaQuest’s Kymera Therapeutics KYMR Stock Holding History

AlphaQuest’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,984
Closed -$466K – 1093
2025
Q4 		$466K Sell
5,984
-94
-2% -$6.35K 0.03% 885
2025
Q3 		$344K Buy
6,078
+988
+19% +$44.6K 0.02% 1070
2025
Q2 		$222K Buy
+5,090
New +$175K 0.02% 1063
2024
Q4 		– Sell
-3,418
Closed -$162K – 1872
2024
Q3 		$162K Sell
3,418
-1,794
-34% -$79.2K 0.01% 1148
2024
Q2 		$156K Buy
5,212
+4,865
+1,402% +$168K 0.02% 826
2024
Q1 		$13.9K Sell
347
-2,717
-89% -$97.2K ﹤0.01% 1061
2023
Q4 		$78K Buy
+3,064
New +$54.8K 0.02% 812

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

AlphaQuest's KYMR Position: Q1 2026 in Review

AlphaQuest sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 5,984 shares — an estimated $466K sold.

AlphaQuest first reported a position in KYMR in Q4 2023 and held it in 7 quarters. The position peaked at $466K in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • AlphaQuest reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 5,984 Kymera Therapeutics shares in Q1 2026, an estimated $466K.
  • AlphaQuest first reported a position in Kymera Therapeutics in Q4 2023 and held it in 7 quarters.
  • AlphaQuest's Kymera Therapeutics position peaked at $466K in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.